ADVB (Advanced Biomed) 3-Year RORE % : -452.50% (As of Mar. 2026)


ADVB Advanced Biomed Inc ADVB
12 GF Score
Price $5.07
! 1 Warning Sign
View Full Analysis

What is Advanced Biomed 3-Year RORE %?

Advanced Biomed ADVB +3.10% 12 3-Year RORE % is -452.50 as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 201 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 98.01% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Advanced Biomed's 3-Year RORE % for the quarter that ended in Mar. 2026 was -452.50%.

The industry rank for Advanced Biomed's 3-Year RORE % or its related term are showing as below:

ADVB's 3-Year RORE % is ranked worse than
98.01% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.89 vs ADVB: -452.50

Advanced Biomed  (NAS:ADVB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Advanced Biomed 3-Year RORE % Related Terms


Advanced Biomed 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Advanced Biomed's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Biomed 3-Year RORE % Chart

Advanced Biomed Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
0.00 0.00 0.00 0.00 16.06

Advanced Biomed Quarterly Data
Jun21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.08 16.06 10.79 -417.92 -452.50

ADVB vs MBAI, XWEL, NDRA: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Advanced Biomed's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Biomed 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Advanced Biomed's 3-Year RORE % falls into.


ADVB
12GF Score
Advanced Biomed Inc ADVB
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advanced Biomed 3-Year RORE % Calculation

Advanced Biomed's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 4.76--3.376 )/( -1.798-0 )
=8.136/-1.798
=-452.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -452.50 mean?
Advanced Biomed (ADVB) has a 3-Year RORE % of -452.50 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #197 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 98%.
Is Advanced Biomed's 3-Year RORE % too high?
Advanced Biomed's current 3-Year RORE % is -452.50. Based on the distribution chart, Advanced Biomed ranks #197 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's 3-Year RORE % compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #197 out of 201 companies for 3-Year RORE %. This places Advanced Biomed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Advanced Biomed and its competitors. Advanced Biomed's current 3-Year RORE % is -452.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current 3-Year RORE % of -452.50. The current 3-Year RORE % is -452.50. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current 3-Year RORE % is -452.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Biomed Business Description

Address No. 689-85 Xiaodong Road, Yongkang District, Tainan, TWN
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score

Get the complete analysis for ADVB

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.07
Price